# US 2010/0167300 A1 · MICROENVIRONMENT NICHE ASSAY FOR CiPS SCREENING

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167300 A1
- Document ID: US20100167300A1
- Status: Published application
- Kind: A1
- Application number: 12/637,738
- Filed: 2009-12-14
- Published: 2010-07-01
- Earliest claimed: 2008-12-13
- Assignees: DNAmicroarray, Inc.
- Inventors: Babak Esmaeli-Azad
- Web page: https://patentgrep.com/patent/US20100167300A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 2501/02: Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
- C12N 2501/065: Modulators of histone acetylation
- C12N 2501/415: Wnt; Frizzeled
- C12N 2503/00: Use of cells in diagnostics
- C12N 2506/1307: from adult fibroblasts
- C12N 2533/30: Synthetic polymers
- C12N 2539/00: Supports and/or coatings for cell culture characterised by properties
- G01N 33/5073: {Stem cells}
- G01N 2500/10: involving cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides three-dimensional microenvironment niches prepared from biomaterial compositions that supports growth and self renewal of stem cells. The invention also provides methods for inducing pluripotency in a somatic cell using chemical compounds, as well as methods for screening for compounds that can induce pluripotency in a somatic cell.

## Claims

### Claim 1

A three-dimensional microenvironment niche comprising a biomaterial composition that supports growth and self renewal of a stem cell.

### Claim 2 (depends on 1)

The three-dimensional microenvironment niche of claim 1, wherein the stem cell is an embryonic stem cell.

### Claim 3 (depends on 2)

The three-dimensional microenvironment niche of claim 2, wherein the embryonic stem cell is a human embryonic stem cell.

### Claim 4 (depends on 1)

The three-dimensional microenvironment niche of claim 1, wherein the biomaterial culture composition comprises a polymer hydrogel.

### Claim 5 (depends on 4)

The three-dimensional microenvironment niche of claim 4, wherein the polymer is hyaluronan.

### Claim 6 (depends on 1)

The three-dimensional microenvironment niche of claim 1, wherein the biomaterial culture composition comprises at least one component selected from: laminin, fibronectin, vitronectin; epidermal growth factor; fibroblast growth factor; Noggin; SIS; and EHS basement membrane.

### Claim 7 (depends on 6)

The three-dimensional microenvironment niche of claim 6, wherein the component is present in a soluble culture medium.

### Claim 8 (depends on 1)

A method for inducing pluripotency of somatic cell, comprising the steps of:
a) providing a somatic cell in contact with the three dimensional microenvironment niche of claim 1;
b) contacting the somatic cell with at least one compound that induces expression of at least one endogenous pluripotency factor.

### Claim 9 (depends on 8)

The method of claim 8, wherein the somatic cell does not express a pluripotency factor from an exogenous polynucleotide sequence.

### Claim 10 (depends on 8)

The method of claim 8, wherein the somatic cell is embedded in the three dimensional microenvironment niche.

### Claim 11 (depends on 8)

The method of claim 8, wherein the at least one endogenous pluripotency factor is selected from: OCT3/4, SOX2, LIN28, KLF4, cMYC and NANOG.

### Claim 12 (depends on 8)

The method of claim 8, wherein the compound activates a Wnt pathway, activates a Cyclooxygenase pathway, or inhibits a p53 activity.

### Claim 13 (depends on 8)

The method of claim 8, wherein the at least one compounds is selected from 6-bromoindirubin-3′-oxime (BIO); indirubin-5-nitro-3′-oxime (INO); valproic acid; 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine; 1-(4-Methylphenyl)-2-(4,5,6,7-tetrahydro-2-imino-3(2H)-benzothiazolyl)ethanone HBr (Pifithrin-α); prostaglandin J2; and prostaglandin E2.

### Claim 14 (depends on 8)

The method of claim 8, wherein pluripotency is induced by a combination comprising of 6-bromoindirubin-3′-oxime (BIO); indirubin-5-nitro-3′-oxime (INO); valproic acid; 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine; 1-(4-Methylphenyl)-2-(4,5,6,7-tetrahydro-2-imino-3(2H)-benzothiazolyl)ethanone HBr (Pifithrin-α); prostaglandin J2; and prostaglandin E2.

### Claim 15 (depends on 8)

A pluripotent cell prepared according to the method of claim 8.

### Claim 16 (depends on 15)

A culture comprising a plurality of cells according to claim 15 and a three-dimensional microenvironment niche comprising a biomaterial culture composition that supports growth and self renewal of a stem cell.

### Claim 17 (depends on 1)

A method of screening for compounds that induce pluripotency of a somatic cell, comprising:
a) contacting a test compound with a somatic cell, wherein the somatic cell is in contact with the three dimensional microenvironment niche of claim 1;
b) measuring expression of an endogenous pluripotency factor in the somatic cell; and
c) selecting the test compound that increases the expression of the endogenous pluripotency factor in the somatic cell,
wherein an increase in the expression of the endogenous pluripotency factor in the somatic cell correlates to induction of pluripotency.

### Claim 18 (depends on 16)

The method of claim 16, wherein the pluripotency factor is selected from OCT3/4, SOX2, LIN28, KLF4, cMYC and NANOG.

### Claim 19 (depends on 16)

The method of claim 16, wherein the pluripotency factor is OCT4 or SOX2.

### Claim 20 (depends on 16)

The method of claim 16, further comprising:
e) Confirming that the compound induces pluripotency by:
i) providing a ViPS cell, wherein the ViPS cell has been induced to a pluripotent state by expression of at least one exogenous polynucleotide sequence encoding a pluripotency factor, wherein the ViPS cell displays a pluripotent characteristic;
ii) providing a test cell that is identical to the ViPS cell except that the test cell does not express the exogenous polynucleotide encoding the endogenous pluripotency factor of step b), wherein the test cell does not displays the pluripotent characteristic;
iii) contacting the test cell with the compound,
iv) determining whether the contacted test cell displays the pluripotent characteristic; and
v) selecting the test compound that restores the pluripotent characteristic to the test cell.

### Claim 21 (depends on 20)

The method of claim 20, wherein the pluripotent characteristic is: self-renewal; ES cell morphology in vitro; expression of a pluripotency biomarker selected from SSEA-3, SSEA-4, TRA-1-60, TRA-1-81 and OCT4; absence of expression of biomarker SSEA-1; demethylation of an Oct4 or a NANOG promoter relative to a somatic cell; ability to form teratomas in SCID mice; ability to give rise to ectoderm, mesoderm, and endoderm.

### Claim 22

A CiPS cell, wherein pluripotency is induced in the cell by at least one chemical that activates at least one endogenous pluripotency factor.

### Claim 23 (depends on 22)

The CiPS cell of claim 22, wherein the at least one endogenous pluripotency factor is selected from OCT3/4, SOX2, LIN28, KLF4, cMYC and NANOG

### Claim 24 (depends on 23)

The CiPS cell of claim 23, wherein the at least one chemical is selected from 6-bromoindirubin-3′-oxime (BIO); indirubin-5-nitro-3′-oxime (INO); valproic acid; 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine; 1-(4-Methylphenyl)-2-(4,5,6,7-tetrahydro-2-imino-3(2H)-benzothiazolyl)ethanone HBr (Pifithrin-α); prostaglandin J2; and prostaglandin E2.
